Featured image for “Oticon Launches Reveal Hearing Aids with Dual AI Processing and Expanded Connectivity”
Aug. 12, 2026

Oticon Launches Reveal Hearing Aids with Dual AI Processing and Expanded Connectivity

HHTM
Oticon has introduced Oticon Reveal™, a new hearing aid platform featuring what the company describes as the world’s first Dual AI system for hearing aids. The new platform uses two dedicated AI systems—one focused on speech and another on contextual sounds—with the goal of providing clearer speech while preserving meaningful sounds in the surrounding environment. Oticon Reveal also incorporates a
Featured image for “Samsung Galaxy Buds Hearing Aid Feature Receives FDA Clearance”
Aug. 11, 2026

Samsung Galaxy Buds Hearing Aid Feature Receives FDA Clearance

HHTM
Samsung Electronics announced that its Galaxy Buds Hearing Aid feature has received clearance from the U.S. Food and Drug Administration (FDA), allowing compatible Galaxy Buds1 to function as over-the-counter (OTC) hearing aids2 for adults age 18 and older with perceived mild to moderate hearing loss. The feature is designed for users who may have difficulty following conversations in noisy environments
Featured image for “When Accessibility Goes Mainstream: Captions, AI and What Comes Next”
Aug. 11, 2026

When Accessibility Goes Mainstream: Captions, AI and What Comes Next

HHTM
Accessible communication technology is advancing rapidly, but building tools that people can truly depend on requires more than simply adding artificial intelligence. Brian Taylor speaks with InnoCaption CEO Paul Lee about the evolution of captioned communication, the company’s milestone of supporting more than 30 million captioned calls, and the importance of keeping users at the center of accessibility technology. Lee
Featured image for “Skylark Bio Doses First Patient in Gene Therapy Trial for GJB2-Related Hearing Loss”
Aug. 11, 2026

Skylark Bio Doses First Patient in Gene Therapy Trial for GJB2-Related Hearing Loss

HHTM
CAMBRIDGE, MASSACHUSSETTS — Skylark Bio, a clinical-stage biotechnology company developing targeted genetic medicines for hearing loss and other monogenic disorders, announced that the first patient has been dosed in the SONIX Phase 1/2 clinical trial evaluating SKY-GJB2, the company’s investigational inner-ear-targeted gene therapy for GJB2-mediated hearing loss. “Dosing the first patient in SONIX brings us one step closer to a future
Featured image for “GN Debuts ReSound Sensia Hearing Aids with New AI Platform and DNN Noise Reduction”
Aug. 10, 2026

GN Debuts ReSound Sensia Hearing Aids with New AI Platform and DNN Noise Reduction

HHTM
BALLERUP, DENMARK — GN has announced ReSound Sensia™, a family of premium hearing aids built on the company’s new AI platform and designed to improve access to a listener’s intended speech in complex listening environments. The new platform combines real-time environmental classification, 4-microphone directional beamforming, and Deep Neural Network (DNN) noise reduction. According to GN, the technologies work together to identify
Featured image for “Starkey Omega AI Wins Healthcare Eagles Award for Best Use of Artificial Intelligence”
Aug. 10, 2026

Starkey Omega AI Wins Healthcare Eagles Award for Best Use of Artificial Intelligence

HHTM
EDEN PRAIRIE, MINNESOTA — Starkey announced that its Omega AI hearing technology has been named a winner in the Best Use of Artificial Intelligence category at the 2026 Healthcare Eagles Awards. The recognition honors organizations and technologies using artificial intelligence to advance healthcare outcomes, improve patient experiences, and support innovation across the industry. Omega AI is Starkey’s latest hearing technology
Featured image for “Sonorous Neurovascular Enrolls First Canadian Patient in B-SILENT Pulsatile Tinnitus Study”
Aug. 07, 2026

Sonorous Neurovascular Enrolls First Canadian Patient in B-SILENT Pulsatile Tinnitus Study

HHTM
LAKE FOREST, CALIFORNIA — Sonorous Neurovascular has enrolled the first Canadian patient in its international B-SILENT clinical study evaluating the investigational BosSTENT™ for the treatment of debilitating pulsatile tinnitus associated with symptomatic cerebral venous sinus stenosis. The enrollment took place at The Ottawa Hospital under principal investigator Dr. Robert Fahed and marks the study’s expansion into Canada. The B-SILENT study
Featured image for “Hearing Aids Are Not Like Glasses — and It’s Time the Industry Said So”
Aug. 06, 2026

Hearing Aids Are Not Like Glasses — and It’s Time the Industry Said So

HHTM
When someone gets glasses, a blurry world usually snaps into sharp focus. So it’s no surprise that many new hearing aid users — and their families — expect the same experience: put in the devices, hear normally again. When that doesn’t happen, disappointment follows. Devices end up in drawers. Families grow frustrated. And the expectation gap that caused it all
Featured image for “Using DTx to Improve the “Stickiness” of Care”
Aug. 04, 2026

Using DTx to Improve the “Stickiness” of Care

HHTM
Editor’s note: Ear to the Ground is a new monthly column from Dr. Brian Taylor, offering timely reflections on research, technology, clinical practice, and emerging trends in hearing care. You can read last month’s column here. Nothing is more frustrating than thoroughly guiding a new patient through the process of using new hearing aids, only to have them quickly abandon
Featured image for “Starkey Cares Hosts a Hearing Event for Individuals with Usher Syndrome”
Aug. 04, 2026

Starkey Cares Hosts a Hearing Event for Individuals with Usher Syndrome

HHTM
EDEN PRAIRIE, MINNESOTA — Starkey recently welcomed individuals from across the country affected by Usher syndrome to its headquarters for a special Starkey Cares hearing event held in conjunction with the 2026 Usher Syndrome Coalition Conference. Through Starkey Cares, the company provided comprehensive hearing evaluations and fit 20 qualified individuals with hearing aids, helping improve access to hearing technology for